Indacaterol Maleate

Generic Details

Generic Name

Indacaterol-Maleate

Other Names

  • Arcoxia

Drug Class

  • Long-acting beta2-adrenergic agonist (LABA)

Chemical Formula

C24H28N2O3.C4H4O4

Molecular Weight

601.62 g/mol

Mechanism of Action

  • Indacaterol exerts its pharmacological effects through selective agonism of beta2-adrenergic receptors in the lungs, resulting in bronchodilation.

Indications

  • Indacaterol-Maleate is indicated for the maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Common Dosage Forms

  • Inhalation powder
  • Aerosol

Typical Dosage

  • 75 mcg once-daily

Pediatric Dosage

  • Not established

Geriatric Dosage

  • Dosage adjustment may be needed based on individual patient response and tolerability.

Side Effects

  • Common side effects include headache, cough, nasopharyngitis, and back pain. Serious side effects may include paradoxical bronchospasm, cardiovascular effects, and hypersensitivity reactions.

Contraindications

  • Hypersensitivity to indacaterol or any component of the product.

Pregnancy Category

  • Category C - Risk cannot be ruled out.

Lactation Safety

  • Limited data available; caution advised.

Drug Interactions

  • Concomitant use with other long-acting beta-agonists (LABA) may potentiate adverse effects.

Overdose Symptoms

  • Possible symptoms of overdose include tremor, headache, palpitations, and tachycardia.

Antidote for Overdose

  • Supportive care and monitoring; beta-blockers may antagonize the effects of indacaterol.

Storage Conditions

  • Store at controlled room temperature, between 20-25°C (68-77°F). Protect from light and moisture.

Pharmacokinetics

  • Absorption: Rapidly absorbed after inhalation
  • Distribution: Highly protein-bound
  • Metabolism: Primarily hepatic via CYP3A4
  • Excretion: Mainly via feces

Precautions

  • Caution in patients with cardiovascular disorders, hyperthyroidism, diabetes, seizures, and hypokalemia.

Warnings

  • Indacaterol is not indicated for the treatment of acute bronchospasm or asthma exacerbations; should not be initiated in patients with acutely deteriorating COPD.

Others

  • Regularly monitor patients for respiratory function and cardiovascular effects during treatment.